Qiang Liu

21PUBLICATIONS
90CO-AUTHORS
Gene and molecular therapyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Sep 09, 2026
Neoadjuvant Pertuzumab Biosimilar HLX11 Versus Reference Pertuzumab for Early-stage or Locally Advanced Breast Cancer: A phase 3 Equivalence Trial.

|May 13, 2026
NFYA-Mediated TTK Up-Regulation Drives Fast Cell Cycle Progression and Its Inhibition Leads to Mitotic Catastrophe in Triple Negative Breast Cancer.

|Apr 04, 2026
Everolimus destabilizes thymidylate synthase via suppressing its O-GlcNAcylation and sensitizes HER2-negative breast cancer to fluorouracil.

Xiao-Ting Jiang, Huipei Gan, Shaoyi Wang

|Jan 12, 2026
De-escalation of axillary surgery after neoadjuvant therapy in breast cancer: long-term outcomes of sentinel lymph node biopsy alone versus complete axillary lymph node dissection.

Haizhu Chen, Xiaoyan Qian, Luhui Mao

|Sep 30, 2025
Chemotherapy-induced CA-repeat DNA fragments in breast cancer trigger antitumor immune responses.

Xiaoqian Zhang, Penghan Huang, Huiping Chen

|Mar 22, 2025
Dynamic ctDNA tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy.

Shunying Li, Yudong Li, Wei Wei

Pageof 4

Frequent Collaborators

6 joint publications

Erwei Song

4 joint publications

Shicheng Su

2 joint publications

Xiaoqian Zhang

2 joint publications

Jinna Lin